Corcept Therapeutics Inc
A California drugmaker that tames the stress hormone cortisol, which the body pumps out in excess in some illnesses. Its best-known medicine, Korlym, treats Cushing's syndrome, a condition where too much cortisol causes high blood sugar and other troubles. Founded in 1998 by two Stanford psychiatrists, the company got its name from a mashup of "cortisol" and "concept." Its founding idea grew out of a Stanford researcher's hunch that the abortion pill mifepristone could also block cortisol's effects — a hunch that later became its flagship drug.
Granted 1.00M · Sold 400.0K
Granted 140.0K · Bought 100.0K
Granted 350.0K · Sold 10.0K
Granted 90.0K · Sold 47.4K
Granted 410.0K
Granted 726.1K · Sold 696.0K
Granted 255.0K · Sold 70.1K
Granted 91.9K · Sold 80.0K
Granted 425.4K · Sold 429.0K
Granted 325.9K · Sold 321.4K
Granted 52.3K · Sold 52.3K
Granted 11.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Belanoff Joseph KChief Executive Officer, Director · 42 transactions | — | 6.36M | 1.00M | — | 400.0K |
| Baker G Leonard JrDirector · 9 transactions | +4.1% | 5.53M | 140.0K | 100.0K | — |
| Wilson James NDirector · 24 transactions | — | 2.82M | 350.0K | — | 10.0K |
| Mahoney David LDirector · 16 transactions | -2.1% | 2.55M | 90.0K | — | 47.4K |
| Hunt HazelChief Scientific Officer · 8 transactions | +249.2% | 255.4K | 410.0K | — | — |
| Maduck SeanSee Remarks · 130 transactions | — | 137.7K | 726.1K | — | 696.0K |
| Robb Gary CharlesChief Business Officer · 90 transactions | — | 125.0K | 255.0K | — | 70.1K |
| Mokari AtabakChief Financial Officer · 41 transactions | +875% | 56.1K | 91.9K | — | 80.0K |
| Guyer WilliamChief Development Officer · 85 transactions | — | 29.5K | 425.4K | — | 429.0K |
| Lyon Joseph DouglasSee Remarks · 106 transactions | -27.6% | 7.0K | 325.9K | — | 321.4K |
| Swisher Daniel N JRDirector · 52 transactions | -22.8% | 2.2K | 52.3K | — | 52.3K |
| Cannon GillianDirector · 3 transactions | — | 0 | 11.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -2.01M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.